Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Correlation of SARS-CoV-2 Breakthrough Infections to Time-from-vaccine; Preliminary Study
Barak Mizrahi, Roni Lotan, Nir Kalkstein, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 73

Showing 1-25 of 73 citing articles:

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 16, pp. 1532-1546
Open Access | Times Cited: 2091
Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression
Daniel R. Feikin, Melissa M. Higdon, Laith J. Abu‐Raddad, et al.
The Lancet (2022) Vol. 399, Iss. 10328, pp. 924-944
Open Access | Times Cited: 1082
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 669
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 24
Open Access | Times Cited: 553
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2127-2135
Open Access | Times Cited: 533
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2136-2143
Open Access | Times Cited: 416
Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2
Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2108-2110
Open Access | Times Cited: 234
Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections
Sivan Gazit, Roei Shlezinger, Galit Perez, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 177
Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK
Nick Andrews, Elise Tessier, Julia Stowe, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 167
Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine
Tal Patalon, Sivan Gazit, Virginia E. Pitzer, et al.
JAMA Internal Medicine (2021) Vol. 182, Iss. 2, pp. 179-179
Open Access | Times Cited: 144
Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 141
Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel
Ottavia Prunas, Joshua L. Warren, Forrest W. Crawford, et al.
Science (2022) Vol. 375, Iss. 6585, pp. 1151-1154
Open Access | Times Cited: 139
Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review
Kin Israel Notarte, Israel Guerrero‐Arguero, Jacqueline Veronica Velasco, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 2939-2961
Open Access | Times Cited: 116
COVID vaccine boosters: the most important questions
Ewen Callaway
Nature (2021) Vol. 596, Iss. 7871, pp. 178-180
Open Access | Times Cited: 113
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
Yair Goldberg, Micha Mandel, Yinon M. Bar-On, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 109
COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study
Miloslav Klugar, Abanoub Riad, Lekshmi Mohanan, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1437-1437
Open Access | Times Cited: 106
COVID-19 Vaccine Booster: To Boost or Not to Boost
Rahul Shekhar, Ishan Garg, Suman Pal, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 4, pp. 924-929
Open Access | Times Cited: 104
Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
Pinkus Tober‐Lau, Tatjana Schwarz, Kanika Vanshylla, et al.
The Lancet Respiratory Medicine (2021) Vol. 9, Iss. 11, pp. e104-e105
Open Access | Times Cited: 74
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2) variant in Qatar
Patrick Tang, Mohammad R. Hasan, Hiam Chemaitelly, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 71
Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against covid-19 related symptoms in England: test negative case-control study
Nick Andrews, Julia Stowe, Freja Kirsebom, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 61
Covid-19 booster vaccines: What we know and who’s doing what
Elisabeth Mahase
BMJ (2021), pp. n2082-n2082
Closed Access | Times Cited: 57
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
Robert W Aldridge, Alexei Yavlinsky, Vincent Nguyen, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 54
A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease
Melissa M. Higdon, Brian Wahl, Carli B. Jones, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 49
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar
Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases
Michael D. Kappelman, Kimberly N. Weaver, Xian Zhang, et al.
The American Journal of Gastroenterology (2021) Vol. 117, Iss. 3, pp. 462-469
Closed Access | Times Cited: 40
Page 1 - Next Page

Scroll to top